Literature DB >> 20109341

Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.

Lu Han1, Shao-Jun Lin, Jian-Ji Pan, Chuan-Ben Chen, Yu Zhang, Xiu-Chun Zhang, Xi-Yi Liao, Qi-Song Chen.   

Abstract

BACKGROUND AND
OBJECTIVE: Radiotherapy is effective in treating nasopharyngeal carcinoma (NPC). This study evaluated the treatment efficacy, toxicity, and prognostic factors of intensity-modulated radiotherapy (IMRT) in the treatment NPC.
METHODS: Between September 2003 and September 2006, 305 patients with NPC were treated with IMRT in Fujian Provincial Cancer Hospital. IMRT was delivered as follows: gross tumor volume (GTV) received 66.0-69.8 Gy in 30-33 fractions, high-risk clinical target volume (CTV-1) received 60.0-66.65 Gy, low-risk clinical target volume (CTV-2) and clinical target volume of cervical lymph node regions (CTV-N) received 54.0-55.8 Gy. Patients with stages III or IV disease also received cisplatin-based chemotherapy. All patients were assessed for local-regional control, survival, and toxicity.
RESULTS: With a median follow-up of 35 months (range, 5-61 months), there were 16, 8, and 39 patients who had developed local, regional, and distant recurrence, respectively. The 3-year rates of local control, regional control, metastasis-free survival, disease-free survival, and overall survival were 94.3%, 97.7%, 86.1%, 80.3%, and 89.1%, respectively. Multivariate analyses revealed that T-classification had no predictive value for local control and survival, whereas N-classification was a significant prognostic factor for overall survival (P < 0.001), metastasis-free survival (P < 0.001), and disease-free survival (P = 0.003). For stages III-IV disease, concurrent and adjuvant chemotherapy did not influence prognosis. The most severe acute toxicities included Grade III mucositis in 14 patients (4.6%), Grade III skin desquamation in 90 (29.5%), and Grades III-IV leucocytopenia in 20 (6.5%). There were 7% patients with Grade II xerostomia after 2 years of IMRT, no Grades 3 or 4 xerostomia was detected.
CONCLUSIONS: IMRT provided favorable locoregional control and survival rates for patients with NPC, even in those with locally advanced disease. The acute and late toxicities were acceptable. N-classification was the main factor of prognosis. Further study is needed on chemotherapy for patients with NPC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109341     DOI: 10.5732/cjc.009.10332

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


  33 in total

1.  Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma.

Authors:  Wei Lu Kuang; Qin Zhou; Liang Fang Shen
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

2.  Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xiayun He; He Xiayun; Dan Ou; Hongmei Ying; Guopei Zhu; Chaosu Hu; Taifu Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-26       Impact factor: 2.503

3.  A new T staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results from a prospective multicentric clinical study.

Authors:  Min Kang; Pingting Zhou; Tingting Wei; Tingting Zhao; Jianxiong Long; Guisheng Li; Haolin Yan; Guosheng Feng; Meilian Liu; Jinxian Zhu; Rensheng Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 4.  Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers.

Authors:  S A Bhide; K L Newbold; K J Harrington; C M Nutting
Journal:  Br J Radiol       Date:  2012-05       Impact factor: 3.039

5.  Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.

Authors:  Si Wei Li; Hua Wang; Mei Lian Liu; Hai Bo Zhang; Yan Qun Xiang; Xing Lv; Wei Xiong Xia; Mu Sheng Zeng; Hai Qiang Mai; Ming Huang Hong; Xiang Guo
Journal:  Med Oncol       Date:  2012-12-15       Impact factor: 3.064

6.  Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9.

Authors:  Shengqun Luo; Guoliang Huang; Ziyou Wang; Zheng Wan; Hua Chen; Dan Liao; Chuyan Chen; Huahui Li; Binbin Li; Liyong Chen; Zunnan Huang; Zhiwei He
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study.

Authors:  Rensheng Wang; Fang Wu; Heming Lu; Bo Wei; Guosheng Feng; Guisheng Li; Meilian Liu; Haolin Yan; Jinxian Zhu; Yong Zhang; Kai Hu
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-18       Impact factor: 4.553

8.  Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa.

Authors:  Cheng-Long Huang; Rui Guo; Jun-Yan Li; Cheng Xu; Yan-Ping Mao; Li Tian; Ai-Hua Lin; Ying Sun; Jun Ma; Ling-Long Tang
Journal:  Eur Radiol       Date:  2019-10-24       Impact factor: 5.315

9.  Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

Authors:  Can Xiao; Lili Wang; Yang Jiao; Kekang Sun; Songbing Qin; Xiaoting Xu; Jian Guo; Juying Zhou
Journal:  Mol Clin Oncol       Date:  2013-02-05

10.  HLA-A*02-B*46 haplotype: an adverse prognostic factor in Han patients with nasopharyngeal carcinoma.

Authors:  Ruo-Zheng Wang; Dian-Gang Zhang; Ran Wu; Yun-Hui Hu; Yan-Chun Peng; Cheng Chang; Tao Dong; Xi-Yan Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.